Allergy Immunotherapy Market To Reach $4.1 Billion By 2033

Allergy Immunotherapy Market Growth & Trends

The global allergy immunotherapy market size is expected to reach USD 4.1 billion by 2033 registering a CAGR of 8.9% from 2026 to 2033, according to a new report by Grand View Research, Inc. Rising prevalence of allergic conditions is expected to boost the market growth. According to the statistics published by the American Academy of Allergy, Asthma & Immunology (AAAAI), global prevalence of allergic rhinitis ranges from 10% to 30%. The disease affects 7.8% of the adult population in U.S. alone.

Technological advancements in the field of bioengineering and immunology have improved the composition of allergy shots given to patients for boosting the immune system. In addition, efforts to overcome the problems associated with safety, efficacy, standardization, costs, and long duration of immunotherapy is also expected to propel the market growth in the coming years. Europe occupied the largest market share in 2019 and will retain its leading position during the forecast period. However, Asia Pacific is estimated to be the fastest-growing regional market from 2020 to 2027.

 Request a free sample copy or view report summary: Allergy Immunotherapy Market Report

Allergy Immunotherapy Market Report Highlights

• The inhalant allergen immunotherapy segment dominated the market with the largest share of 92.4% in 2025, driven by the high prevalence of respiratory allergic diseases, including allergic rhinitis and allergic asthma, associated with allergens such as house dust mites, grass pollen, tree pollen, and ragweed.

• The subcutaneous immunotherapy (SCIT) segment dominated the allergy immunotherapy industry with the largest share of 58.6% in 2025, supported by its established clinical efficacy in treating allergic rhinitis, allergic asthma, and venom allergies.

• The allergic rhinitis segment dominated the allergy immunotherapy market with the largest share of 72.8% in 2025, driven by the high global prevalence of the condition and the established role of allergen immunotherapy as the only disease-modifying treatment capable of providing sustained symptom relief while reducing disease progression.

• The adult segment dominated the market with the largest share of 69.8% in 2025, driven by the high prevalence of allergic rhinitis and allergic asthma, higher diagnosis rates, and greater utilization of allergen immunotherapy in specialty allergy clinics.

• The hospital pharmacies segment dominated the market with the largest share of 48.6% in 2025, driven by the administration requirements of allergen immunotherapy, particularly subcutaneous immunotherapy (SCIT), which requires physician supervision, post-injection patient monitoring, and immediate access to emergency care for potential systemic allergic reactions.

• The Europe allergy immunotherapy market accounted for the largest revenue share of 61.6% in 2025. The market is driven by the increasing adoption of allergen immunotherapy as a long-term treatment for allergic diseases and the growing emphasis on disease-modifying therapies.

Allergy Immunotherapy Market Segmentation

Grand View Research has segmented the global smart toilet market based on application, distribution channel, and region.

Allergy Immunotherapy Product Type Outlook (Revenue, USD Million/Billion, 2021 - 2033)

• Inhalant Allergen Immunotherapy

  • Grass Pollen Immunotherapy

  • Tree Pollen Immunotherapy

  • Weed Pollen Immunotherapy

  • House Dust Mite Immunotherapy

  • Animal Dander Immunotherapy

  • Mold (Fungal) Immunotherapy

• Venom Allergen Immunotherapy

  • Bee Venom Immunotherapy

  • Wasp Venom Immunotherapy

  • Ant Venom Immunotherapy

• Food Allergen Immunotherapy

  • Peanut Allergy Immunotherapy

  • Milk Allergy Immunotherapy

  • Egg Allergy Immunotherapy

  • Others

Allergy Immunotherapy Route of Administration Outlook (Revenue, USD Million/Billion, 2021 - 2033)

• Subcutaneous Immunotherapy (SCIT)

• Sublingual Immunotherapy (SLIT)

Allergy Immunotherapy Indication Outlook (Revenue, USD Million/Billion, 2021 - 2033)

• Allergic Rhinitis

• Allergic Asthma

• Insect Sting Allergy

• Food Allergy

• Atopic Dermatitis

Allergy Immunotherapy Patient Group Outlook (Revenue, USD Million/Billion, 2021 - 2033)

• Pediatric

• Adult

Allergy Immunotherapy Distribution Channel Outlook (Revenue, USD Million/Billion, 2021 - 2033)

• Hospital Pharmacies

• Retail Pharmacies

• Online Pharmacies

Allergy Immunotherapy Regional Outlook (Revenue, USD Million/Billion, 2021 - 2033)

• North America

  • U.S.

  • Canada

  • Mexico

• Europe

  • Germany

  • UK

  • France

  • Italy

  • Spain

  • Denmark

  • Sweden

  • Norway

• Asia Pacific

  • Japan

  • China

  • India

  • Australia

  • South Korea

  • Thailand

• Latin America

  • Brazil

  • Argentina

• Middle East and Africa (MEA)

  • South Africa

  • Saudi Arabia

  • UAE

  • Kuwait

List of Key Players in Allergy Immunotherapy Market

• ALK-Abello

• Stallergenes Greer

• Allergy Therapeutics

• HAL Allergy.

• Leti Pharma

• Aimmune Therapeutics.

• DBV Technologies

• HollisterStier Allergy (Jubilant HollisterStier LLC)

• Immunotek

• Allergopharma.

• Diater

• Roxall

• Probelte

• Lofarma